Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Korosho to Consider Introduction of “Special Nurses”
April 5, 2010
- Korosho to Approve Orphan Drugs Earlier
April 5, 2010
- Reclassification to Be Considered for 7 Class 1 OTC Drugs
April 5, 2010
- Industry Should Be Prepared for Discussions to Perpetuate New Pricing System: Mr Nagano
April 5, 2010
- Combination Eye Drops Improve Compliance: Prof. Yamamoto
April 5, 2010
- Application for Eritoran to Be Delayed Until March 2011: Eisai
April 5, 2010
- IFN Beta + Ribavirin Added to First-Line Therapy for Hepatitis C
April 5, 2010
- Alogliptin Applied for Combination with SU, BU as Additional Indications
April 5, 2010
- Cooperation of Pharmacists and Nurses Is Necessary for XELOX Therapy
April 5, 2010
- Towa to Increase Its Number of MRs to 450
March 29, 2010
- Ghrelin Attracts Attention at Protein Mall Kansai
March 29, 2010
- PMDA to Review Applications for Priority Products within 10 Months
March 29, 2010
- 74th JCS Annual Scientific Meeting
March 29, 2010
- Value-Based Generics Use Rate of 6.6% Reported by Kyokai Kenpo
March 29, 2010
- Discussions Started on Vaccination Act Amendment
March 29, 2010
- Takata Seiyaku Takes Over 5 Shionogi Brands
March 29, 2010
- Osaka Pref. Demands That Korosho Accept Return of Flu Vaccines
March 29, 2010
- No Serious Concern about Domestic Flu Vaccines
March 29, 2010
- Pharmacists Should Provide More Personalized Medication Guidance: Mr Isobe
March 29, 2010
- In the Blink of an Eye
Philip Carrigan
Partner, Optia Partners
philip@optiapartners.com
March 29, 2010
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…